IQVIA HOLDINGS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 226.7 USD | -1.26% |
|
-1.47% | -2.02% |
| May. 28 | Weight-loss drug forecasts jump to $150 billion as supply grows | RE |
| May. 14 | Transcript : IQVIA Holdings Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 09:20 AM |
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- One of the major weak points of the company is its financial situation.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 31.31 times its estimated earnings per share for the ongoing year.
- With an enterprise value anticipated at 3.47 times the sales for the current fiscal year, the company turns out to be overvalued.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.02% | 41.83B | B | ||
| +54.05% | 63.85B | B- | ||
| +40.01% | 40.47B | A | ||
| -10.22% | 27.17B | C | ||
| +13.42% | 26.52B | B- | ||
| -21.60% | 18.69B | B | ||
| +2.89% | 12.73B | B+ | ||
| +22.40% | 12.11B | B+ | ||
| +27.49% | 12.07B | C+ | ||
| -9.26% | 11.19B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- IQV Stock
- Ratings Iqvia Holdings Inc.
